CN101363846B - Quality-control product of freeze-drying human lymphocyte surface antigen and method for making same - Google Patents
Quality-control product of freeze-drying human lymphocyte surface antigen and method for making same Download PDFInfo
- Publication number
- CN101363846B CN101363846B CN200810150909A CN200810150909A CN101363846B CN 101363846 B CN101363846 B CN 101363846B CN 200810150909 A CN200810150909 A CN 200810150909A CN 200810150909 A CN200810150909 A CN 200810150909A CN 101363846 B CN101363846 B CN 101363846B
- Authority
- CN
- China
- Prior art keywords
- quality
- value
- surface antigen
- cell
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 52
- 238000003908 quality control method Methods 0.000 title claims abstract description 36
- 239000000427 antigen Substances 0.000 title claims abstract description 33
- 102000036639 antigens Human genes 0.000 title claims abstract description 33
- 108091007433 antigens Proteins 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title abstract description 23
- 238000004108 freeze drying Methods 0.000 title description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims abstract description 27
- 239000006285 cell suspension Substances 0.000 claims abstract description 18
- 230000007935 neutral effect Effects 0.000 claims abstract description 9
- 239000003223 protective agent Substances 0.000 claims abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 23
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 23
- 229910052791 calcium Inorganic materials 0.000 claims description 23
- 239000011575 calcium Substances 0.000 claims description 23
- 229910052749 magnesium Inorganic materials 0.000 claims description 23
- 239000011777 magnesium Substances 0.000 claims description 23
- 239000003855 balanced salt solution Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 4
- 235000012204 lemonade/lime carbonate Nutrition 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 238000010166 immunofluorescence Methods 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract description 2
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 239000008098 formaldehyde solution Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000047 product Substances 0.000 description 28
- 239000007788 liquid Substances 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 5
- 230000000527 lymphocytic effect Effects 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000000247 postprecipitation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a product for controlling the quality of lyophilized human lymphocyte surface antigens, which is a grey-white solid prepared by lyophilizing a cell suspension having a cell concentration of 400,000-600,000/mL and containing lyophilized human lymphocytes immobilized by a neutral buffer formaldehyde solution and a protective agent. The mark values respectively are: CD3 of 37.25-69.1%, CD4 of 17.9-33.7%, CD8 of 12.4-23.9%, and the ratio of CD4/CD8 of 0.98-1.94. The invention also provides the preparation method of the quality control product. The product has the characteristics of good antigen storability and stable antigenicity, and can be used for the quality control reagent for detecting the lymphocyte surface mark antigenicity (CD series) by adopting the cell analyzer method, the immunofluorescence method, the immunoenzyme method, a SPA (Staphylococcus aureus A protein) rosettes method and the like.
Description
Technical field
The present invention relates to the quality-control product in the Medical Immunology, relate in particular to a kind of quality-control product of drying human lymphocyte surface antigen and preparation method thereof.
Background technology
Lymphocyte plays central role in whole machine body immune response process.In PBL, lymphocyte accounts for 20%～50% [absolute value (1～3.3) * 10
9/ L], it mainly comprises T cell, B cell and NK cell.Because lymphocyte is inhomogenous cell colony; It has comprised many subgroups with different immunologic functions; Therefore measure the lymphocytic cell surface mark with immunological technique, can be used for judging the immunologic function of human body, help the prevention and health care of human body and diagnosis, treatment and the prognosis of disease.
At present; The method of measuring the lymphocytic cell surface mark is a lot; But which kind of method no matter; All be the principle of applied immunology antigen-antibody reaction, promptly the monoclonal antibody specific of measured surface sign and lymphocyte reaction show that through adopting different mode (like fluorescence, dyeing or garland) positive cell obtains the result's.
Current; Measure the monoclonal antibody (McAb) of lymphocyte CD series and worldwide carried out scale, commercialization production, different CDMcAb manufacturers, different CD McAb kind and the assay method of lymphocyte subgroup are selected according to the actual conditions of self in each laboratory.At present; Because the detection method that each laboratory is selected for use is different; The experimental apparatus model differs, and Chinese lymphocyte subgroup reference value still do not have unified final conclusion, therefore in real work temporary transient with reference to the reference value in the kit instructions of being selected for use separately as criterion; Thereby cause the reliability of lymphocyte subgroup testing result, comparability poor, detect difficult quality guarantee.
" national clinical examination working specification " at present (Department of Medical Administration of Ministry of Health of the People's Republic of China compiles, the third edition, publishing house of Southeast China University, 2007:349; Second edition 1997:381-384 and first published 1991:286-287) in the reagent that is used for the quality control that cellular immunity detects of regulation be to use the lymphocyte alive of liquid nitrogen cryopreservation; This reagent is selected qualified donor through trial test; Get anti-freezing (heparin or ethylenediamine tetraacetic acid) blood on an empty stomach from vein, isolated lymphocytes is washed 2～3 times; Be suspended in the cell freezing preservation liquid and obtain; Carry out then preserving in the rearmounted liquid nitrogen of a small amount of packing, liquid nitrogen container places freezer, in every batch of test, is used as quality control.During use, from liquid nitrogen container, take out a cell cryopreservation pipe, move into rapidly in 37 ℃ of water-baths and recover; The sucking-off cell suspension is centrifugal in another centrifuge tube, abandons supernatant, washs 2～3 times; Add quantitative cell suspending liquid according to purposes and suspend, it is subsequent use to be adjusted to required cell concentration.But in this technology, cell must freezing preservation in liquid nitrogen, and liquid nitrogen container must place freezer, preserves that requirement condition is strict, appointed condition is harsh, makes necessary expense very high; Simultaneously because what preserve is the cell of living, in case that operating process and experiment condition have slightly is improper, cell just is easy to damage and death; Thereby influence cellular antigens property and test findings; Therefore common this condition of the Chang Yinwu of clinical labororatory can't be carried out this test with ability, and the person of having ready conditions when reality is used often owing to cell separation, frozen, recovery process technology requirement height, complicated operation; Waste time and energy, and the term of validity is short and be difficult to effectively promoted.
Because lymphocyte surface antigen belongs to labile antigen, in the preservation process, very easily lose, therefore use the lymphocyte quality-control product of living, can't solve the problem of widespread usage in the real work.
Summary of the invention
Technical matters to be solved by this invention provides and a kind ofly makes lymphocyte lose BA and preserve its antigen active, and keeps the breadboard different operating person's who is applicable to different people lymphocyte surface antigen detection method, different region, different condition of lymphocyte morphosis quality-control product of drying human lymphocyte surface antigen as much as possible.
Another technical matters to be solved by this invention provides the preparation method that the cryodesiccated method of a kind of usefulness makes the lymphocyte surface antigen quality-control product of drying human lymphocyte surface antigen that exists steady in a long-term.
For addressing the above problem, a kind of quality-control product of drying human lymphocyte surface antigen of the present invention is characterized in that: the cell concentration that it is made up of human lymphocyte after fixing agent is fixing and protective agent is the cell suspension of 400～6,000,000/mL; Its sign value is CD3
+: 37.2～69.1%, CD4
+: 17.9～33.7%, CD8
+: 12.4～23.9%, CD4
+/ CD8
+: 0.98～1.94.
Said fixing agent is that volumetric concentration is 0.02%～4%, the pH value is 7.0～7.4 neutral buffered formalin; This solution is meant that with distilled water and mass concentration be after 40% formaldehyde mixes by the volume ratio of 9:1; Add lime carbonate; Make it be hypersaturated state; Promptly obtain the pH value and be 7.0, mass concentration is 4% neutral formalin solution, is that 7.0～7.4 no calcium, magnesium Han Keshi balanced salt solution are formulated by the volume ratio of 1:99～0 with this neutral formalin solution and pH value then.
Said protective agent is that mass concentration is 0.15～2.5%, the pH value is 7.0～7.4 no calcium, magnesium Han Keshi gelatin solution; This solution is that 0.15～2.5 gram gelatin is dissolved in 100mL pH value is in 7.0～7.4 no calcium, the magnesium Han Keshi balanced salt solution, and is formulated after filtering.
A kind of preparation method of aforesaid quality-control product of drying human lymphocyte surface antigen may further comprise the steps:
(1) select qualified donor through trial test, venous blood samples, adding the pH value with the volume ratio of 1:1～3 is 7.0～7.4 no calcium, magnesium Han Keshi balanced salt solution, mixing is superimposed upon on the lymphocyte separation medium, and is centrifugal;
(2) get mononuclearcell, using pH value is after 7.0～7.4 no calcium, magnesium Han Keshi balanced salt solution wash, centrifugal, abandons supernatant;
(3) cell of post precipitation being used the pH value is that 7.0～7.4 no calcium, magnesium Han Keshi balanced salt solution are diluted to 400～6,000,000/mL cell suspension, drips then in fixing agent; Stir fixing 0.25～48h down at-20～30 ℃, get the fixed cell suspension;
(4) the fixed cell suspension is filtered with nylon mesh after, centrifugal, abandon supernatant; Using the pH value again is to abandon supernatant after 7.0～7.4 no calcium, magnesium Han Keshi balanced salt solution or the distilled water washing, the fixed cell deposition;
(5) protective agent is added in the fixed cell deposition, is made into 400～6,000,000/mL cell suspension, be sub-packed in frozen pipe or ampere bottle with the amount of every bottle of 0.2～1.0mL after, place-80～-20 ℃ of refrigerator and cooled to freeze 4～72h at once;
(6) with the freeze drier precooling to-38～-42 ℃, take out the frozen pipe or the ampere bottle that fill cell suspension and put into freeze drier, take out behind freeze-drying 4～18h, seal immediately, and frozen pipe or ampere bottle put-20 ℃～4 ℃ preserve down and get final product.
Venous blood in the said step (1) adopts heparin or ethylenediamine tetraacetic acid anti-coagulants to extract.
The cell suspension in the said step (3) and the volume ratio of fixing agent are 1:5～20.
Nylon mesh in the said step (4) is 200～450 orders.
The application of a kind of aforesaid quality-control product of drying human lymphocyte surface antigen in the human lymphocyte surface antigen detects; It is characterized in that: during use; In human lymphocyte surface antigen quality-control product, add in the no calcium, magnesium Han Keshi balanced salt solution, the no calcium that contains 20% newborn calf serum, magnesium Han Keshi balanced salt solution, phosphate buffer, distilled water of 100～1000 μ L any one; Make its dissolving, the pH value of wherein said no calcium, magnesium Han Keshi balanced salt solution or phosphate buffer is 7.0～7.4.
The present invention compared with prior art has the following advantages:
1, because the present invention is the dried frozen aquatic products after fixing through fixing agent, be that surface antigen is preserved the active lymphocyte of good inanimate object, so antigenicity is stable, the term of validity is grown to 2～5 years, reliable in quality.
2, because the present invention be dried frozen aquatic products and sealing, and its volume, weight are little, can be lower than 25 ℃ normal temperature down or-20 ℃～4 ℃ transportations, preservation, latter's first-selection need not special technique and condition, so can reduce storage expenses greatly.
3, the present invention does not need specific installation and condition in using, and is simple to operate, can carry out Quality Control work adaptable across common clinical labororatory, thereby promotes and improve active quality and the level that detects of human lymphocyte surface antigen.
4, product price of the present invention is cheap, is easy to get the transportation convenient storage.
5, product of the present invention can be used as methods detection lymphocytic cell surface sign (CD series) antigenic quality control reagent (with reference to article) such as flow cytometer method, immunofluorescence technique, immunoenzyme, SPA (staphylococcal protein A) garland method, and is used for other test items (acceptor) of relevant lymphocytic cell surface sign and the indoor and outdoor Quality Control of method; Also can be used for detecting simultaneously lymphocytic cell surface sign McAb affinity, tire, detection such as type, estimate lymphocyte surface antigen McAb.
6, as to product of the present invention through International or National Quality Control relevant speciality department---demarcate antigen active like WHO (World Health Organization (WHO)), IUIS (international immunology federation), ministry of Health of China clinical examination centralab after; Can provide International or National one-level, secondary with reference to article;, be used for the lymphocyte surface antigen quality control, estimate monoclonal antibody (McAb) quality and McAb quality control with reference to article as lymphocyte surface antigen quality control unified standard.
Embodiment
1 one kinds of quality-control product of drying human lymphocyte surface antigen of embodiment, the cell concentration that it is made up of human lymphocyte after formalin is fixing and gelatin solution is the cell suspension of 400～6,000,000/mL, after freeze-drying, is the cotton-shaped solid of canescence; Adopt the flow cytometer method to measure lymphocyte subgroup (CD), obtaining its sign value is CD3
+: 37.2～69.1%, CD4
+: 17.9～33.7%, CD8
+: 12.4～23.9%, CD4
+/ CD8
+: 0.98～1.94.
The preparation method of above-mentioned quality-control product of drying human lymphocyte surface antigen is following:
(1) at first through 18～38 years old sex cellular immune function---lymphocyte CD 3 to healthy, non-communicable disease and other acute and chronic disease, no disease of immune system
+, CD4
+, CD8
+, CD4
+/ CD8
+Detect, the normal person of result is confirmed as the qualified donor of trial test.
Then the qualified donor of trial test is adopted heparin or ethylenediamine tetraacetic acid anti-coagulants venous blood samples on an empty stomach; Adding the pH value with the volume ratio of 1:1～3 is 7.0～7.4 no calcium, magnesium Han Keshi balanced salt solution (no calcium, magnesium Hank ' S liquid); Mixing; Be superimposed upon lymphocyte separation medium (source: blood disease research institute of the Chinese Academy of Medical Sciences), with the centrifugal 15～30min of the rotating speed of 1500～2500rpm.
(2) get mononuclearcell (PBMC), the pH value of using 5～10 times of amounts is after 7.0～7.4 no calcium, magnesium Hank ' S liquid wash 2～3 times, with the centrifugal 5～10min of the rotating speed of 500～1500rpm, to abandon supernatant.
(3) cell of post precipitation being used the pH value is that 7.0～7.4 no calcium, magnesium Han Keshi balanced salt solution are diluted to 400～6,000,000/mL cell suspension; Drip then in the pH value be 7.0～7.4, volumetric concentration is that the volume ratio of cell suspension and formalin is 1:5～20 in 0.02%～4% the buffering formalin; Stir fixing 0.25～48h at-20～30 ℃ of lower magnetic forces, get the fixed cell suspension.
Wherein formalin is meant with distilled water and mass concentration to be after 40% formaldehyde mixes by the volume ratio of 9:1, to add lime carbonate, makes it be hypersaturated state, promptly obtains the pH value and be 7.0, mass concentration is 4% neutral formalin solution; Be that 7.0～7.4 no calcium, magnesium Han Keshi balanced salt solution are formulated by the volume ratio of 1:99～0 with this neutral formalin solution and pH value then.
(4) the fixed cell suspension that step (3) is obtained filters the back with 200～450 order nylon mesh and moves in 5～50mL centrifuge tube, with the centrifugal 5～10min of the rotating speed of 500～2500rpm, abandons supernatant; Using the pH value again is to abandon supernatant after 7.0～7.4 no calcium, magnesium Hank ' S liquid or the distilled water washing 2～3 times, the fixed cell deposition.
(5) 0.15～2.5 gram gelatin being dissolved in 100mL pH value is in 7.0～7.4 no calcium, the magnesium Han Keshi balanced salt solution, with the gelatin solution that is mixed with 0.15～2.5% after the filtration of 100～200 order nylon mesh.
This gelatin solution is added in the fixed cell deposition that step (4) obtains; Behind the mixing with the method counting cells of blood count; Be made into 400～6,000,000/mL cell suspension; Obtain being added with the fixed cell suspension of freeze drying protectant, be sub-packed in frozen pipe or ampere bottle with the amount of every bottle of 0.2～1.0mL then after, place-80～-20 ℃ of refrigerator and cooled to freeze 4～72h at once.
(6) with extremely-38～-42 ℃ of freeze drier precoolings; Taking-up fills the frozen pipe or the ampere bottle of cell suspension and puts into freeze drier (must guard against freezing thing dissolving) rapidly; Take out behind freeze-drying 4～18h, seal immediately, and frozen pipe or ampere bottle are put-20 ℃～4 ℃ preserve down and get final product.
Aforesaid operations all carries out under gnotobasis.
When embodiment 2 is applied to flow cytometer method detection lymphocyte subgroup (CD) when this quality-control product of drying human lymphocyte surface antigen, in human lymphocyte surface antigen quality-control product, add no calcium, magnesium Hank ' the S liquid of 100～1000 μ L, pH=7.0～7.4; Perhaps in quality-control product, add 100～1000 μ L, volumetric molar concentration is the phosphate buffer (PBS) of 0.01mol/L, pH=7.0～7.4; The distilled water that perhaps in quality-control product, adds 100～1000 μ L, dissolving, and then with the filtration of 250～450 purpose nylon mesh, subsequent use.
When embodiment 3 is applied to immunofluorescence technique, AP-AAP bridging enzyme immunoassay detection lymphocyte subgroup (CD) when this quality-control product of drying human lymphocyte surface antigen, in human lymphocyte surface antigen quality-control product, add the no calcium that contains 20% newborn calf serum, magnesium Hank ' the S liquid of 100～1000 μ L, pH=7.0～7.4; Perhaps in quality-control product, add 100～1000 μ L, volumetric molar concentration is the PBS that contains 20% newborn calf serum of 0.01mol/L, pH=7.0～7.4; The distilled water that contains 20% newborn calf serum that perhaps in quality-control product, adds 100～1000 μ L, the dissolving back is subsequent use.
Embodiment 4 is when this quality-control product of drying human lymphocyte surface antigen is applied to monoclonal antibody SPA garland method (McAb-A-E direct method or indirect method) when detecting lymphocyte subgroup (CD), in human lymphocyte surface antigen quality-control product, adds 100～1000 μ L, pH value and be 7.0～7.4 no calcium, magnesium Hank ' S liquid; The distilled water that perhaps in quality-control product, adds 100～1000 μ L, the dissolving back is subsequent use.
Should be appreciated that the embodiment that discusses and embodiment can propose various improvement and variation just in order to explain to the people who is familiar with this field here, these improvement and variation will be included in the application's spirit and the scope and appended claim scope.
Claims (1)
1. quality-control product of drying human lymphocyte surface antigen is characterized in that: the cell concentration that it is made up of human lymphocyte after fixing agent is fixing and protective agent is the cell suspension of 400～6,000,000/mL; Its sign value is CD3
+: 37.2～69.1%, CD4
+: 17.9～33.7%, CD8
+: 12.4～23.9%, CD4
+/ CD8
+: 0.98～1.94; Said fixing agent is that volumetric concentration is 0.02%～4%, the pH value is 7.0～7.4 neutral buffered formalin; This solution is meant that with distilled water and mass concentration be after 40% formaldehyde mixes by 9: 1 volume ratio; Add lime carbonate; Make it be hypersaturated state; Promptly obtain the pH value and be 7.0, mass concentration is 4% neutral formalin solution, is that 7.0～7.4 no calcium, magnesium Han Keshi balanced salt solution are formulated by 1: 99～0 volume ratio with this neutral formalin solution and pH value then; Said protective agent is that mass concentration is 0.15～2.5%, the pH value is 7.0～7.4 no calcium, magnesium Han Keshi gelatin solution; This solution is that 0.15～2.5 gram gelatin is dissolved in 100mL pH value is in 7.0～7.4 no calcium, the magnesium Han Keshi balanced salt solution, and is formulated after filtering.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810150909A CN101363846B (en) | 2008-09-05 | 2008-09-05 | Quality-control product of freeze-drying human lymphocyte surface antigen and method for making same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810150909A CN101363846B (en) | 2008-09-05 | 2008-09-05 | Quality-control product of freeze-drying human lymphocyte surface antigen and method for making same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101363846A CN101363846A (en) | 2009-02-11 |
| CN101363846B true CN101363846B (en) | 2012-10-10 |
Family
ID=40390327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810150909A Expired - Fee Related CN101363846B (en) | 2008-09-05 | 2008-09-05 | Quality-control product of freeze-drying human lymphocyte surface antigen and method for making same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101363846B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8900864B2 (en) | 2010-09-21 | 2014-12-02 | Nordrhein-Wesfalen Krankenhausbetriebsgesellschaft Bad Oeynhausen mbH | Stabilized leukocytes and their use |
| CN107576788A (en) * | 2017-11-03 | 2018-01-12 | 深圳市巴德生物科技有限公司 | A kind of reference product for detecting leukocyte differentiation antigen and preparation method thereof |
| CN107576790A (en) * | 2017-11-03 | 2018-01-12 | 深圳市巴德生物科技有限公司 | A kind of drying human lymphocyte CD4 surface antigen quality-control products and preparation method thereof |
| CN111351930A (en) * | 2020-02-20 | 2020-06-30 | 泛肽生物科技(浙江)有限公司 | Quality control product of active human lymphocyte surface antigen and preparation method thereof |
| CN111528219B (en) * | 2020-05-13 | 2022-03-15 | 上海市计量测试技术研究院 | A lyophilized protective agent for T lymphocyte subset counting standard substance and its application |
| CN114152739A (en) * | 2021-12-08 | 2022-03-08 | 江西赛基生物技术有限公司 | Fluorescent antibody freeze-dried pellet and preparation method thereof |
-
2008
- 2008-09-05 CN CN200810150909A patent/CN101363846B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 吴瑜等.淋巴细胞免疫表型质控品的初步研究.《临床输血与检验》.2008,201-206. * |
| 王建中等.流式细胞术计数淋巴细胞亚群的全血质控品的研究.《中华检验医学杂志》.2005,897-901. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101363846A (en) | 2009-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101363846B (en) | Quality-control product of freeze-drying human lymphocyte surface antigen and method for making same | |
| CN101949944A (en) | Triiodothyronine quantitative detection kit and preparation method thereof | |
| CN101358968B (en) | Quality control product of freeze-dried human lymphocyte surface antigen and method for preparing same | |
| CN101980723A (en) | Antibodies to clostridium difficile spores and uses thereof | |
| CN103777013B (en) | Colibacillary micro-fluidic chip and method in a kind of detection water | |
| CN102426239A (en) | Colloidal gold chromatographic test strip for rapidly testing lead ion | |
| CN104820102A (en) | Kit of detecting the content of Lp-PLA2 and CRP on the basis of chemiluminescence, and method and application thereof | |
| CN101403752A (en) | Chemical luminescence ELISA detection kit for gatifloxacin | |
| CN101592661A (en) | The brucellosis antibody competition enzyme-linked immunosorbent adsorption test detection kit | |
| CN101320041B (en) | Colloidal gold method for fast quantitative determination of C-reaction protein and its application | |
| CN101241135B (en) | ELISA kit for detecting chlopyrifos residue and method of use thereof | |
| CN101571544A (en) | Islet cell antibody chemiluminescence immunoassay kit and preparation method thereof | |
| CN102539412A (en) | Magnetic particle chemical luminous kit for detecting clenbuterol and application thereof | |
| CN101957364A (en) | Preparation method of lyophilization type platelet antigen spectrum cells | |
| CN101713778A (en) | Detection kit for ciprofloxacin and detection method thereof | |
| CN103954772B (en) | Three gold mark detection test paper bars of a kind of CSFV, pig breeding and respiratory disorder syndrome virus, Pseudorabies virus antibody | |
| CN102507934A (en) | Time-resolved fluoroimmunoassay (TRFIA) of Klebsiella oxytoca | |
| CN103134927A (en) | Method used for detecting shigella and reagent box | |
| CN109342718A (en) | A kind of magnetic microparticle chemiluminescence detection method | |
| CN101368964A (en) | Chemical luminescence method immune analysis diagnostic reagent kit for detecting cytomegalovirus IgG antibody | |
| CN101368965A (en) | Chemical luminescence method immune analysis diagnostic reagent kit for detecting cytomegalovirus IgM antibody | |
| CN102928407A (en) | Magnetic particle chemiluminescence kit for detecting avermectins, and applications thereof | |
| CN101109752B (en) | Method for detecting lymphocyte subgroup with mono-clone antibody SPA hematid rosette method | |
| CN105866409A (en) | Candida mannan antigen immunoassay kit and preparation method and application thereof | |
| US4460694A (en) | Bovine glycoproteins and use in diagnosing infectious mononucleosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121010 Termination date: 20150905 |
|
| EXPY | Termination of patent right or utility model |